Aurobindo Pharma gains on inaugurating biologics contract manufacturing facility 'TheraNym'
Aurobindo Pharma is currently trading at Rs. 1464.60, up by 24.30 points or 1.69% from its previous closing of Rs. 1440.30 on the BSE.
The scrip opened at Rs. 1444.40 and has touched a high and low of Rs. 1465.00 and Rs. 1431.55 respectively. So far 32239 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1550.00 on 21-May-2026 and a 52 week low of Rs. 1017.00 on 02-Sep-2025.
Last one week high and low of the scrip stood at Rs. 1,550.00 and Rs. 1,365.25 respectively. The current market cap of the company is Rs. 84264.09 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.11% and 7.08% respectively.
Aurobindo Pharma has inaugurated TheraNym, one of India's largest dedicated biologics contract manufacturing organisations (CMO). TheraNym represents Aurobindo Pharma’s bold and strategic foray into biologics contract manufacturing - a segment that is growing worldwide and is increasingly vital to meeting global demand for biologic therapies.
The facility is strategically located in Borapatla approximately 45 minutes from the Hyderabad’s bustling Financial District and is equipped with 15 KL bioreactors, advanced downstream processing suites, aseptic fill-finish capabilities, and quality control laboratories. TheraNym has been designed with international regulatory expectations in mind. The facility is intended to support MSD supply chain, both domestic and export markets, subject to applicable approvals and customer requirements.
